Practical Considerations and Implementation of Sodium-Glucose Co-Transporter-2 Inhibitors in Chronic Kidney Disease: Who, When, and How? A Position Statement by Nephrologists

By sjmartinez • August 15, 2024

Rastogi A, Collins A, Kelepouris E, Kotzker W, Middleton JP, Rajpal M, Roy-Chaudhury P, Chertow GM. Practical Considerations and Implementation of Sodium-Glucose Co-Transporter-2 Inhibitors in Chronic Kidney Disease: Who, When, and How? A Position Statement by Nephrologists. J Prim Care Community Health. 2024 Jan-Dec;15:21501319241259905. doi: 10.1177/21501319241259905. PMID: 39143759.

Tags: Chronic kidney disease, consensus, KDIGO, Nephrology, Publications, SGLT2 inhibitor, treatment algorithm

A Unique Case of a Mildly Symptomatic Patient With Severe Hypokalemia Secondary to Furosemide

Dao KT, Dhillon A, Uddin SS, Eppanapally S, Lai H. A Unique Case of a Mildly Symptomatic Patient With Severe Hypokalemia Secondary to Furosemide. J[...]

Semaglutide and kidney function: direct kidney protection or an artifact?

Ayoub I, Wong G, Glassock RJ. Semaglutide and kidney function: direct kidney protection or an artifact? Kidney Int. 2024 Nov 18:S0085-2538(24)00793-2. doi: 10.1016/j.kint.2024.11.003. Epub ahead[...]

Association of Fibroblast Growth Factor 23 and Cardiac Mechanics in the Cardiovascular Health Study

Jain K, Katz R, Isakova T, Kizer JR, Sharma S, Psaty BM, Shah S, Ix J, Mehta R. Association of Fibroblast Growth Factor 23 and[...]